Medicinal Chemistry News and Research

RSS

Phase 2 clinical trial tests LMP744 for the treatment of first-time recurrent glioblastoma

Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent glioblastoma patients.

25 Feb 2026

Calibr-Skaggs and Kainomyx join forces to accelerate development of antimalarial drugs

The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc., today announced a new research collaboration to accelerate the discovery and development of next-generation antimalarial drugs.

17 Feb 2026

Thermodynamic insights into histamine H1 receptor ligand binding

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs.

13 Feb 2026

Lower hinge of immunoglobulin G acts as a critical immune control hub

The lower hinge of immunoglobulin G (IgG), an overlooked part of the antibody, acts as a structural and functional control hub, according to a study by researchers at Science Tokyo.

31 Jan 2026

Scientists uncover new mechanism initiating gene transcription

Scientists at IOCB Prague are uncovering new details of gene transcription. They have identified a previously unknown molecular mechanism by which the transcription of genetic information from deoxyribonucleic acid (DNA) into ribonucleic acid (RNA) can be initiated.

30 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

New publication describes the chemical journey of non-hormonal male birth control pill

A newly published manuscript authored by Dr. Gunda Georg, YourChoice Therapeutics and Columbia University Medical Center describes the chemical journey of YCT-529, a non-hormonal male birth control pill, and the promising molecular science behind it.

12 Jan 2026

UC Davis team creates new class of serotonin-effecting drugs

UC Davis researchers have developed a new method that uses light to transform amino acids - the building blocks of proteins - into molecules that are similar in structure to psychedelics and mimic their interaction with the brain.

8 Jan 2026

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Discover how AI, flow chemistry, and NMR come together in the PiPAC project to revolutionize scalable and autonomous API production.

From Bruker BioSpin Division 17 Dec 2025

New insights into alcohol-related DNA damage and cancer risk

Alcohol consumption leads to the formation of a toxic compound called acetaldehyde, which damages DNA.

15 Dec 2025

Exclusive licensing agreement accelerates PHD inhibitor development for anemia in CKD patients

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused pharmaceutical company, as well as TaiGen Biopharmaceuticals, its wholly-owned Beijing subsidiary (both referred to as "TaiGen"), today announced an exclusive pipeline out-licensing collaboration.

12 Dec 2025

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint blockades in solid cancers.

12 Dec 2025

Older chemical libraries yield new leads for next-generation COVID-19 antivirals

SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid.

8 Dec 2025

Study shines light on how P2X4 receptor can be inhibited

A study carried out by the University of Bonn and the University Hospital Bonn throws light on how an important receptor can be inhibited.

5 Dec 2025

Generative AI aids discovery of ISM3830's novel scaffold

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, playing a central role in modulating T-cell activation and immune tolerance, and its inhibition enhances T cells and NK cells function, also provides a strategy for the function restoration of exhausted T cells.

1 Dec 2025

New fluorescent labeling method offers high precision and exceptional stability in living cells

A team of researchers at IOCB Prague headed by Dr. Tomáš Slanina has developed a new method for labeling molecules with fluorescent dyes that surpasses existing approaches in both precision and stability.

21 Nov 2025

Molecular bumpers and glues rewire GPCR signaling for next-generation medicines

New research led by the University of Minnesota Medical School demonstrates that molecules acting as "molecular bumpers" and "molecular glues" can rewire G protein-coupled receptor (GPCR) signaling, turning the cell's busiest receptors into precision tools - opening the door to a new generation of safer, smarter medicines.

31 Oct 2025